spacer
home > white papers > Case Study: Cmed’s Mobile Data Management Solution - Cmed Clinical Services
WHITE PAPERS
logo_Cmed_Clini.JPG

Cmed Clinical Services

phone +44 (0) 1403 755050
email info@cmedresearch.com
web http://www.cmedresearch.com
email Holmwood, Broadlands Business Campus, Langhurstwood Road, Horsham, West Sussex, RH12 4QP, UK

Case Study: Cmed’s Mobile Data Management Solution

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers.

The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Genome & Company Chooses Luina Bio to Supply Innovative Drug Productfor Clinical Trials Programme

Luina Bio, a leading biopharmaceutical manufacturing company in Australia, today announced it will develop and produce an innovative bacterial drug product for Genome & Company to support its clinical trials programme. The relationship signals Luina Bio’s first foray into Asia and further establishes its global leadership in the current Good Manufacturing Practise for microbiome projects.
More info >>


White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>


Industry Events

PHARM Connect Congress 2019

12-13 March 2019, Budapest Congress Center, Hungary

PHARM Connect Congress is the premier networking business event dedicated to pharmaceutical and biotechnology innovations and trends from development through commercialisation in Central and Eastern Europe. The organiser - TEG The Events Group - cordially welcome all lead business professionals, academicians, researchers and peers from the field of pharmaceutical manufacturing and biotechnology to participate in the upcoming Congress.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement